Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.50 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591747 | 0.84 | MTNR1B (0.46) | MTNR1BMTNR1AMAPT | |
| SCHEMBL21591699 | 0.82 | MTNR1B (0.51) | MTNR1BMTNR1ANNMTMEN1KMT2A | |
| SCHEMBL21591711 | 0.81 | MTNR1A (0.53) | MTNR1BMTNR1ANNMTMAPT | |
| SCHEMBL6028212 | 0.78 | KMT2A (0.41) | MTNR1BMTNR1ANNMTMEN1KMT2A | |
| SCHEMBL21591735 | 0.75 | MTNR1B (0.45) | MTNR1BMTNR1ANNMT | |
| SCHEMBL21327224 | 0.73 | NNMT (0.50) | MTNR1BMTNR1ANNMTMEN1KMT2A | |
| SCHEMBL4315975 | 0.70 | RECQL (0.43) | MTNR1BMTNR1ANNMTMEN1KMT2A | |
| SCHEMBL2497902 | 0.70 | MTNR1A (0.37) | MTNR1BMTNR1ANNMTMEN1KMT2A | |
| SCHEMBL22123758 | 0.70 | NNMT (0.36) | MTNR1BMTNR1ANNMTMEN1KMT2A | |
| SCHEMBL21327577 | 0.68 | KMT2A (0.40) | MTNR1BMTNR1ANNMTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807270-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |